Assessing Allopurinol Effect on Metabolic Acidosis in Patients with Chronic renal failure stage 2-4

Clinical Trial of Assessing Allopurinol Effect on Metabolic Acidosis in Patients with Chronic renal failure stage 2-4

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016122731604N1

Enrollment

Registered

2017-08-05

Start date

2017-04-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: CKD. Condition 2: CKD stage 2-4. Chronic kidney disease Kidney damage with mild decreased GFR (60-89 mL/min

Interventions

Treatment - Drugs

Intervention 1: allopurinol 1 tablet of Allopurinol 100mg per day in intervention group for 3 mounth. Intervention 2: placebo in control group.

allopurinol 1 tablet of Allopurinol 100mg per day in intervention group for 3 mounth

placebo in control group

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: inclusion:age 18-80,Chronic kidney disease stage 2-4,both gender exclusion:gout,myeloprolifrative disorder,allopurinol user ,allergy to allopurinol, uric acid>10,active infection

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bicarbonate. Timepoint: before intervention,after 3 month. Method of measurement: blood level meq/L.;Uric acid. Timepoint: before intervention,3 month. Method of measurement: blood level mg/mL.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Miri Ghalehnovi

Mashhad University of Medical Siences

mirighm@mums.ac.ir+98 51 3840 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026